이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

HER2 발현 진행성 또는 전이성 고형암 환자를 대상으로 한 HMPL-A251의 1상/2a상 임상시험

2026년 9월 17일 업데이트: Hutchmed

HMPL-A251의 안전성, 내약성, 약동학, 면역원성 및 예비 효능을 평가하기 위한 진행성 또는 전이성 HER2 발현 고형 종양 환자를 대상으로 한 1상/2a상 연구

This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

  • To evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of HMPL-A251 in participants with previously treated HER2+ solid tumors
  • To characterize the safety and preliminary efficacy of HMPL-A251 at RDEs to determine recommended dose(s) for phase 2 (RP2D) or phase 3 (RP3D) in participants with selected HER2-expressing solid tumors

연구 유형

중재적

등록 (추정된)

147

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Colorado
      • Denver, Colorado, 미국, 80218
        • 모병
        • SCRI HealthONE
        • 연락하다:
    • Florida
      • Plantation, Florida, 미국, 33322
      • Plantation, Florida, 미국, 33322
        • 모병
        • Florida Clinical Trials Group LLC (Plantation)
        • 연락하다:
      • Tamarac, Florida, 미국, 33321
        • 아직 모집하지 않음
        • Florida Clinical Trials Group LLC (Tamarac)
        • 연락하다:
          • Chintan Ghandi
    • New Jersey
      • East Brunswick, New Jersey, 미국, 08816
        • 아직 모집하지 않음
        • START New Jersey
        • 연락하다:
          • Bruno Fang
    • New York
      • New York, New York, 미국, 10065
        • 아직 모집하지 않음
        • Memorial Sloan Kettering Cancer Center
        • 연락하다:
          • Vicky Makker
    • Ohio
      • Cleveland, Ohio, 미국, 44195
        • 모병
        • Cleveland Clinic Taussig Cancer Center
        • 연락하다:
    • Washington
      • Tacoma, Washington, 미국, 98405
        • 아직 모집하지 않음
        • Northwest Medical Specialties, PLLC
        • 연락하다:
          • Jorge Chaves
      • Beijing, 중국
        • 모병
        • Peking University First Hospital
        • 연락하다:
        • 연락하다:
          • Yu Fan
      • Changsha, 중국
        • 모병
        • Hunan Cancer Hospital
        • 연락하다:
      • Guangzhou, 중국
        • 모병
        • Sun Yat-sen University Cancer Center
        • 연락하다:
      • Hefei, 중국
        • 모병
        • The First Affiliated Hospital of Anhui Medical University
        • 연락하다:
      • Shanghai, 중국
        • 모병
        • Fudan University Shanghai Cancer Center
        • 연락하다:
          • Jian Zhang
        • 연락하다:
      • Shenyang, 중국
        • 모병
        • The First Hospital of China Medical University
        • 연락하다:
      • Zhengzhou, 중국
        • 모병
        • Henan Cancer Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Histologically confirmed unresectable advanced or metastatic disease.
  2. Have at least one measurable lesion per RECIST v1.1;
  3. Life expectancy ≥ 12 weeks;
  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
  5. Weight ≥ 35 kg;

Exclusion Criteria:

  1. An established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus.
  2. Use of strong inhibitors or strong inducers of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug;
  3. Toxicity from prior anti-tumor therapy has not recovered to Grade 1 or baseline prior to the first dose of study drug (except alopecia). Participants with chronic Grade 2 toxicities may be eligible after discussion between the investigator and Sponsor Medical Monitor (e.g., Grade 2 chemotherapy-induced neuropathy);
  4. Baseline blood amylase or lipase exceeds the normal range and are judged by the investigators to be clinically significant;
  5. Spinal cord compression, leptomeningeal disease, or clinically active central nervous system (CNS) metastases, defined as untreated or symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms;
  6. Major surgery within 28 days prior to the first dose of study drug. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study drug(s);

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 순차적 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Part A(Phase I)

Dose Escalation

Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first.

Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first.

실험적: Part B(Phase IIa)

Dose Expansion/Dose Optimization

Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first.

Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Maximum Tolerated Dose (MTD)
기간: Approximately 12 months

At least three participants will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN) will be used to guide dose escalation and to determine the MTD of HMPL-A251

Approximately 12 months
Recommended doses for expansion (RDE)
기간: Approximately 12 months

The RDE will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data, such as chronic toxicities, discontinuations, or withdrawals for toxicity that occur beyond the DLT period; PK data collected at the time of evaluation; Preliminary efficacy data.

Approximately 12 months
Overview of Treatment-emergent Adverse Events (TEAEs)
기간: Approximately 24 months

All TEAEs will be graded according to NCI CTCAE v6.0 and coded using the Medical Dictionary for Regulatory Activities (MedDRA).

Approximately 24 months
Objective Response Rate (ORR)
기간: At least 6 weeks post dose of first participant up to approximately 24 months

ORR is defined as the proportion of participants with Best objective response (BOR) of confirmed complete response (CR) or partial response (PR), as per investigator's assessment according to RECIST v1.1.

At least 6 weeks post dose of first participant up to approximately 24 months
Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A251
기간: Approximately 12 months

The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data.

Approximately 12 months

2차 결과 측정

결과 측정
측정값 설명
기간
Disease control rate (DCR)
기간: Approximately 2 years

The proportion of participants with BOR of confirmed CR, confirmed PR, or stable disease (SD) lasting at least 5 weeks.

Approximately 2 years
Duration of response (DoR)
기간: Approximately 2 years

Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first occurrence of objective tumor response (CR or PR) to the date of first radiographic PD or death due to any cause.

Approximately 2 years
Time to response (TTR)
기간: Approximately 2 years

Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first dose of study dose to the first occurrence of objective tumor response (CR or PR)

Approximately 2 years
Progression-free survival (PFS)
기간: Approximately 2 years

The time from the first dose of study drug to the date of first radiographic PD per RECIST v1.1 or death due to any cause, whichever occurs first.

Approximately 2 years
Overall survival (OS)
기간: Approximately 2 years

Every 12 weeks (± 7 days) until death, withdrawal of consent for follow-up, lost to follow-up or end of study, whichever occurs first.

Approximately 2 years
Maximum plasma/serum concentration (Cmax)
기간: Cycle 1 and Cycle 3 (21-day cycle)

Observed maximum plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609; only applies to Cycles 1 and 3.

Cycle 1 and Cycle 3 (21-day cycle)
Time to maximum plasma/serum concentration (Tmax)
기간: Cycle 1 and Cycle 3 (21-day cycle)

Time to observed Cmax for HMPL-A251, total anti-HER2 antibody, and HM5041609

Cycle 1 and Cycle 3 (21-day cycle)
Area under the plasma/serum concentration-time curve (AUC)
기간: Cycle 1 and Cycle 3 (21-day cycle)

Derived from the observed plasma/serum concentration-time data for HMPL-A251, total anti-HER2 antibody, and HM5041609 using noncompartmental analysis

Cycle 1 and Cycle 3 (21-day cycle)
Pre-dose plasma/serum concentration (Cmin)
기간: Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months

Observed pre-dose plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609.

Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months
Immunogenicity of HMPL-A251
기간: Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months

Incidence of anti-drug antibody and neutralizing antibody against HMPL-A251

Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 12월 16일

기본 완료 (추정된)

2028년 11월 30일

연구 완료 (추정된)

2028년 12월 31일

연구 등록 날짜

최초 제출

2025년 11월 11일

QC 기준을 충족하는 최초 제출

2025년 11월 13일

처음 게시됨 (실제)

2025년 11월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 22일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 17일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2025-251-GLOB1

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .